steroid 5 alpha-reductase 2 | OKDB#: 992 |
Symbols: | SRD5A2 | Species: | human | ||
Synonyms: | Locus: | 2p23.1 in Homo sapiens |
For retrieval of Nucleotide and Amino Acid sequences please go to:
OMIM
Entrez Gene
Mammalian Reproductive Genetics Endometrium Database Resource Orthologous Genes UCSC Genome Browser GEO Profiles new! Amazonia (transcriptome data) new! R-L INTERACTIONS MGI |
General Comment |
The microsomal enzyme steroid 5 alpha-reductase is responsible for the conversion of testosterone into the more potent
androgen dihydrotestosterone. In man, this steroid acts on a variety of androgen-responsive target tissues to mediate such
diverse endocrine processes as male sexual differentiation in the fetus and prostatic growth in men.
Harris et al. (1992) concluded that SRD5A1 is a minor component of the reductase activity in prostate although the gene was
originally cloned from prostate. On the other hand, SRD5A1 appears to be the predominant isozyme of steroid
5-alpha-reductase in the scalp and elsewhere in the skin.
From a population survey of 828 healthy families comprising 3,000 individuals, Ellis et al. (1998) identified 58 young bald
men (aged 18 to 30 years) and 114 older nonbald men (aged 50 to 70 years) for a case-control comparison. No significant
differences were found between cases and controls in allele, genotype, or haplotype frequencies for RFLPs related to either
the SRD5A1 or the SRD5A2 gene. These findings suggested that the genes encoding the two 5-alpha-reductase
isoenzymes are not associated with male pattern baldness.
NCBI Summary: This gene encodes a microsomal protein expressed at high levels in androgen-sensitive tissues such as the prostate. The encoded protein is active at acidic pH and is sensitive to the 4-azasteroid inhibitor finasteride. Deficiencies in this gene can result in male pseudohermaphroditism, specifically pseudovaginal perineoscrotal hypospadias (PPSH). [provided by RefSeq, Jul 2008] |
||||
General function | Enzyme, Oxidoreductase | ||||
Comment | Evidence for Increased 5α-Reductase Activity During Early Childhood in Daughters of Women with Polycystic Ovary Syndrome. Torchen LC et al. (2016) Polycystic ovary syndrome (PCOS) is a heritable, complex genetic disease. Animal models suggest that androgen exposure at critical developmental stages contributes to disease pathogenesis. We hypothesized that genetic variation resulting in increased androgen production produces the phenotypic features of PCOS by programming during critical developmental periods. Although we have not found evidence for increased in utero androgen levels in cord blood in the daughters of women with PCOS (PCOS-d), target tissue androgen production may be amplified by increased 5α-reductase activity analogous to findings in adult affected women. It is possible to noninvasively test this hypothesis by examining urinary steroid metabolites. We performed this study to investigate whether PCOS-d have altered androgen metabolism during early childhood. Twenty-one PCOS-d, 1-3 years old, and 36 control girls of comparable age were studied at an academic medical center. Urinary steroid metabolites were measured by gas chromatography/mass spectrometry. 24-h steroid excretion rates and precursor to product ratios suggestive of 5α-reductase and 11β-hydroxysteroid dehydrogenase activities were calculated. Age did not differ but weight for length z-scores were higher in PCOS-d compared to control girls (p=0.02). PCOS-d had increased 5α-tetrahydrocortisol:tetrahydrocortisol ratios (p=0.04) suggesting increased global 5α-reductase activity. There was no evidence for differences in 11β-hydroxysteroid dehydrogenase activity. Steroid metabolite excretion was not correlated with weight. Our findings suggest that differences in androgen metabolism are present in early childhood in PCOS-d. Increased 5α-reductase activity could contribute to the development of PCOS by amplifying target tissue androgen action.////////////////// | ||||
Cellular localization | Cytoplasmic | ||||
Comment | candidate123 | ||||
Ovarian function | Follicle development, Antral follicle growth, Steroid metabolism | ||||
Comment | Stewart PM et al 1990 reported 11 patients with polycystic ovary syndrome (hirsutism and oligomenorrhoea), but with no deficiency of 21-hydroxylase or 3 beta-hydroxysteroid dehydrogenase, had abnormal cortisol metabolism. The high ratio of 5 alpha to 5 beta cortisol metabolites in the urine is consistent with enhanced activity of 5 alpha-reductase. Urinary total cortisol metabolites were higher in patients than controls. Increased 5 alpha-reductase activity in liver and skin enhances hepatic cortisol metabolism at the expense of androgen excess and may be the underlying abnormality in polycystic ovary syndrome. Haning RV Jr, et al determined whether 5alpha-reductase 1 and 2 were expressed in the human ovary, and to determine the relative activity of the two enzymes in various ovarian tissues. The ovary apparently expressed mRNA for only 5alpha-reductase 1, whereas the foreskin expressed both 5alpha-reductase 1 and 2. They compared the 5alpha-reductase activity at both pH 5.5 (optimum for 5alpha-reductase 2 activity) and 8.0 (optimum for 5alpha-reductase 1 activity). 5alpha-reductase activity of foreskin at pH 5.5 was 3900 times higher than small follicles, 1500 times higher than ovarian stroma, and 240 times higher than corpora lutea. 5alpha-reductase activity of corpora lutea at pH 5.5 was 17-fold higher than that of follicles (P < 0.01) and 6.5-fold higher than that of ovarian stroma (P < 0.05). 5alpha-Reductase activity of foreskin at pH 8.0 was 93 times higher than small follicles, 51 times higher than corpora lutea, and 170 times higher than ovarian stroma (all P < 0.01). The ratio of 5alpha-reductase activity at pH 5.5 to that at pH 8.0 was higher in foreskin than in corpus luteum (P < 0.05), ovarian stroma (P < 0.01), or ovarian follicles. The ratio was lower in ovarian follicles than in stroma or corpus luteum. | ||||
Expression regulated by | |||||
Comment | |||||
Ovarian localization | Granulosa, Theca | ||||
Comment | Jakimiuk AJ, et al reported 5alpha-reductase activity in women with polycystic ovary syndrome. 5alpha-Reductase 1 and 5alpha-reductase 2 mRNAs were measured in thecal (TC) and granulosa (GC) cells from individual follicles of 18 women with PCOS and 26 regularly cycling control women. Both 5alpha-reductase 1 and 2 mRNA expression was higher in GC than in TC, and 5alpha-reductase 2 mRNA levels were approximately 3-fold higher than 5alpha-reductase 1 mRNA. 5alpha-Reductase 1 and 2 mRNA expression were similar in GC from PCOS and control women, but 5alpha-reductase mRNA was decreased in TC from PCOS follicles. In control women, 5alpha-reductase 2 mRNA was highest in GC from 3- to 5-mm follicles and decreased to undetectable levels in GC from 7-mm follicles. A similar pattern of expression was present in GC from PCOS follicles, but detectable levels of 5alpha-reductase 2 mRNA were present in GC from 7-mm follicles. 5alpha-Reductase activity was measured in whole follicles by measuring the conversion of radiolabeled testosterone to dihydrotestosterone. Kinetic analysis of total 5alpha-reductase activity at physiological pH revealed a Km of 1.46 micromol/L and a maximal velocity of 0.31 nmol/min x mg protein, indicating predominantly type 1 activity. The total 5alpha-reductase activity was approximately 4-fold higher in PCOS follicles than in control follicles. These data demonstrate elevated 5alpha-reductase activity in polycystic ovaries and support the hypothesis that 5alpha-reduced androgens may play a role in the pathogenesis of PCOS. Petrone A et al 1999 reported the usefulness of a 12-month treatment with finasteride in idiophathic and polycystic ovary syndrome-associated hirsutism. | ||||
Follicle stages | Antral, Preovulatory, Corpus luteum | ||||
Comment | |||||
Phenotypes |
PCO (polycystic ovarian syndrome) |
||||
Mutations |
4 mutations
Species: human
Species: human
Species: human
Species: ovine
|
||||
Genomic Region | show genomic region | ||||
Phenotypes and GWAS | show phenotypes and GWAS | ||||
Links |
|
created: | July 4, 2000, midnight | by: |
hsueh email:
home page: |
last update: | March 22, 2020, 4:27 a.m. | by: | hsueh email: |
Click here to return to gene search form